Biocause Pharma(SZ:000627) Bei Jing Shang Bao·2025-08-31 10:09Core Points - *ST Tianmao announced that it is unable to disclose the 2025 semi-annual report within the statutory deadline, leading to the continued suspension of its stock trading [1] - The company had originally planned to disclose the 2025 semi-annual report on August 29, but the preparation of the 2024 annual report and the 2025 first-quarter report is still incomplete [1] - On August 8, the company held its 10th Board of Directors' fourth meeting, where it approved a resolution to voluntarily terminate its stock listing [1] - The stock has been suspended since August 14 due to the inability to disclose the 2025 semi-annual report [1] - A temporary shareholders' meeting was held on August 25, where the resolution to voluntarily terminate the stock listing was approved [1] - Following the shareholders' decision, the company will submit an application to terminate the listing within fifteen trading days [1] - The stock will enter the cash option distribution, exercise declaration, and settlement phase [1] Additional Information - The company was previously issued a delisting risk warning on July 8 due to its failure to disclose the 2024 annual report and the 2025 first-quarter report within the statutory deadline [2] - According to the Shenzhen Stock Exchange listing rules, if the company does not disclose a majority of the board's assurance of the 2024 annual report's authenticity within two months of the delisting risk warning, the exchange will decide to terminate the stock listing [2]